Clinical Trials Browser

NCT06083922 2026-04-16

A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

Phase 2 Recruiting

20 enrolled

Plasma cell

Multiple Myeloma

NCT06523621 2026-04-16

Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel

Phase 2 Active not recruiting

1 enrolled

Plasma cell

Multiple Myeloma

NCT01384513 2026-04-15

A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies

Phase 2 Completed

40 enrolled 15 charts

Classical hematologyDermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Pdgfra-Associated Chronic Eosinophilic Leukemia, Congenital Abnormalities, Anemia, Aplastic, Anemia, Refractory, Hodgkin Disease, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Mastocytosis, Multiple Myeloma, Mycosis Fungoides, Myeloproliferative Disorders, Polycythemia Vera, Recurrence, Sezary Syndrome, Thrombocythemia, Essential, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Leukemia, Myelomonocytic, Juvenile, Primary Myelofibrosis

Clinical Trials

A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel

A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies

Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)

Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma

FORTE

A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"

Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma

Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance

Dose Schedule Study of BCMA Bispecific Antibody, Elranatamab, for Newly Diagnosed Immunoglobulin Light Chain (AL) Amyloidosis

Flu-Mel-Vel

IFM-CRd

IFM2012-03

IFM2014-04

Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia

TAPUR

A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant

Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant

Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial

Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

IMPEDE

Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older

ADVANCE

Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction

Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma

Halt Aging in Survivors of Blood Cancers: the HALTAging-1 Study

IMPACT

Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing

A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies

BOREALIS

IFm2022-01

EMAT

Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

Elranatamab in R/R Multiple Myeloma

CAR- PRISM (PRecision Intervention Smoldering Myeloma)

ELISA in Relapsed/Refractory MM

Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma

Iber-KDd

Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia

Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma

LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma

A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma

GMMG-DADA

Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients

Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients

Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma